Open-Label, Non Randomized Phase 2 Study With Safety Run-In

This study is currently recruiting participants. (see Contacts and Locations)

Verified December 2015 by PIQUR Therapeutics AG

Sponsor:
PIQUR Therapeutics AG

Collaborators:
Oncology Institute of Southern Switzerland
University College London Hospitals
University Hospital, Basel, Switzerland
University Hospital Munich

Information provided by (Responsible Party):
PIQUR Therapeutics AG

ClinicalTrials.gov Identifier:
NCT02249429

First received: September 8, 2014
Last updated: December 16, 2015
Last verified: December 2015
History of Changes

Purpose

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of PQR309 administered orally, as once daily capsules continously in patients with relapsed or refractory lymphomas.

Condition	Intervention	Phase
Lymphoma, Malignant	Drug: PQR309	Phase 1 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma

Genetic and Rare Diseases Information Center resources: Lymphosarcoma

U.S. FDA Resources

Further study details as provided by PIQUR Therapeutics AG:

Primary Outcome Measures:

- Efficacy of PQR309 in patients with relapsed or refractory lymphoma according to Cheson Criteria [4-7] [Time Frame: In average 2 years] [Designated as safety issue: No]

Secondary Outcome Measures:

- To determine overall safety [Time Frame: 2 year] [Designated as safety issue: No]

  Incidence of SAEs, incidence and severity of all AEs, which will include changes of vital signs, physical examinations, body weight and changes of routine laboratory assessments.

Estimated Enrollment: 72
Study Start Date: May 2015
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: PQR309	Drug: PQR309 60 mg or 80 mg PQR309 per oral (p.o.) once daily until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first. Other Name: AKT/PI3K/mTOR

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically confirmed diagnosis* of relapsed or refractory lymphoma, received at least two prior lines of therapy including immuno-chemotherapy. Patients with relapsed Chronic Lymphoid Leukemia (CLL) are eligible if they have received one or more prior lines of any approved standard therapy. * archival biopsies may be used if obtained up to a year prior to enrollment; re-biopsy is strongly recommended if last biopsy was obtained more than a year ago.
2. Only for patients in the Phase 2 part: At least one measurable nodal or extra-nodal lesion defined as follows: Clearly measurable (i.e. well-defined boundaries) in at least two perpendicular dimensions on imaging scan with > 1.5 cm in longest transverse diameter.
3. Age ≥ 18 years
4. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1 (See Appendix 2).
5. Adequate organ system functions defined as:
    a. Absolute neutrophil count (ANC) ≥1.0x109/l
    b. Platelets ≥ 75x109/l
    c. Haemoglobin ≥ 85g/L
    d. Adequate hepatic function, defined as Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) and Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN (or ALT/AST ≤ 5 times ULN in patients with liver involvement)
    e. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN
    f. Fasting glucose < 7.0 mmol/L; Glycated haemoglobin (HbA1c) < 6.4%
6. Ability and willingness to swallow and retain oral medication.
7. Willingness and ability to comply with the trial procedures
8. Female and male patients with reproductive potential must agree to use effective contraception from screening until 90 days after discontinuation of PQR309
9. Signed informed consent

Exclusion Criteria:

Any of the following conditions precludes enrollment of a patient:

1. Immunosuppression due to:
    - Allogeneic hematopoietic stem cell transplant (HSCT)
    - Any immune-suppressive therapy within 4 weeks prior to trial treatment start
    - Known HIV infection
2. Autologous stem cell transplant within 3 months prior to trial treatment start.
3. Concomitant anticancer therapy (e.g. chemotherapy, radiotherapy, hormonal therapy, immunotherapy, biological response modifier,

signal transduction inhibitors).

4. Concomitant treatment with medicinal products that increase the pH (reduce acidity) of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H2-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a wash-out period sufficient to terminate their effect.
5. Use of any investigational drug within 21 days prior to trial treatment start.
6. Patients who experienced National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events (CTCAE) ≥ Grade 3 on PI3K/mTOR inhibitors
7. Any major surgery, chemotherapy or immunotherapy within 21 days prior to trial treatment start.
8. Symptomatic or progressing Central nervous system (CNS) involvement. Exception: Patients with meningeal involvement can be included upon discussion between the sponsor and the investigator.
9. Persisting toxicities NCI CTCAE ≥2 related to prior anticancer therapy
10. Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
11. Severe/unstable angina, myocardial infarction or coronary artery bypass within the last 3 years prior to trial treatment start, symptomatic congestive heart failure New York Heart Association (NYHA) Class 3 or 4, hypertension BP>150/100mmHg
12. A serious active infection at the time of treatment, or another serious underlying medical condition that could impair the ability of the patient to receive treatment.
13. Lack of appropriate contraceptive measures (male and female)
14. Pregnant or lactating women
15. Known HIV infection
16. Significant medical conditions which could jeopardize compliance with the protocol.
17. Uncontrolled diabetes mellitus; patients with controlled diabetes may be enrolled (see fasting glucose and HbA1c levels in inclusion criteria).

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02249429

Contacts

Contact: PIQUR

Locations

Switzerland

Oncology Institute of Southern Switzerland **Recruiting**
Bellinzona, Switzerland
Contact: Tatsuo Satoh, Dr. tatsuo.satoh@piqur.com
Principal Investigator: Anastasios Stathis, Dr. med.

Sponsors and Collaborators

PIQUR Therapeutics AG

Oncology Institute of Southern Switzerland

University College London Hospitals

University Hospital, Basel, Switzerland

University Hospital Munich

Investigators

Principal Investigator: Anastasios Stathis, Dr. med. Oncology Institute of Southern Switzerland

More Information

No publications provided

Responsible Party: PIQUR Therapeutics AG
ClinicalTrials.gov Identifier: NCT02249429 History of Changes

Other Study ID Numbers:	**PQR309-002**
Study First Received:	September 8, 2014
Last Updated:	December 16, 2015
Health Authority:	Switzerland: Swissmedic Germany: Federal Institute for Drugs and Medical Devices United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:

Lymphoma	Lymphoproliferative Disorders
Immune System Diseases	Neoplasms
Immunoproliferative Disorders	Neoplasms by Histologic Type
Lymphatic Diseases	

ClinicalTrials.gov processed this record on February 10, 2016